MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41467-026-69522-w

Медицинская библиотека · Nature communications · 2026

Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial.

Campian Jian L, Le Son B, Ghiaseddin Ashley, Butt Omar H, Manektalia Harshit, Chen Dongjiang, Xu Yifei, Liu Jingxia, Rahman Maryam, Thai Nathan, Leidig William A, Johanns Tanner, Ansstas George, Zhou Alice Y, Pugazenthi Sangami, Dunn Gavin P, Huang Jiayi, Chheda Milan G, Kim Albert H, Leuthardt Eric C, Tran David D

СтатьяКлиническое исследование II фазыРандомизированное исследованиеКлиническое исследование I фазыПеревод в очереди

Аннотация

Immune checkpoint inhibitors (ICIs) show minimal efficacy in recurrent high-grade astrocytoma (rHGA). Laser interstitial thermal therapy (LITT), a minimally invasive cytoreductive approach, may prime rHGA for ICI response. A phase 1/randomized phase 2b trial (ClinicalTrials.gov: NCT02311582 ) was designed to test pembrolizumab in combination with LITT in patients with rHGA. Nine patients were enrolled in the phase I dose-escalation lead-in study. No dose-limiting toxicities were observed and 200 mg of pembrolizumab every three weeks was determined as the recommended phase 2 dose. The phase 2b study was initially designed to randomize (up to 45) patients 1:1 to either LITT followed by pembrolizumab (LITT + PEM) or non-LITT surgery followed by pembrolizumab (NLS + PEM). Phase 2's primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), safety, and immune signature. After 21 patients, based on an independent Data and Safety Monitoring Committee request of unscheduled interim review of accumulating efficacy data, randomization stopped as benefit from NLS + PEM appeared limited, and the subsequent 24 patients received LITT + PEM. The pre-specified study endpoints were achieved. Among 39 per-protocol patients, LITT + PEM (n = 33) improved median OS (11.8 versus 5.2 months) and 18-month survival (42% versus 0%) compared to NLS + PEM (n = 6) (hazard ratio [HR] 0.17; 95% confidence interval [CI], 0.06-0.49; P = 0.0002). Median PFS was longer in LITT + PEM (4.5 versus 1.6 months; HR 0.21; 95% CI, 0.08-0.56; P = 0.0006). In an intent-to-treat sensitivity analysis (n = 21), OS (HR 0.29; 95% CI, 0.10-0.88) and PFS (HR 0.30; 95% CI, 0.10-0.87) again favored LITT + PEM (n = 13). Treatment was well tolerated. LITT activated non-classical monocytes, and pembrolizumab unleashed CD8⁺ T cell proliferation, clonal expansion, and coordinated memory T-cell responses. Overall, LITT + PEM is safe and may overcome rHGA immunosuppression to generate antitumor immunity.

Для цитирования: Campian Jian L, Le Son B, Ghiaseddin Ashley, Butt Omar H, Manektalia Harshit, Chen Dongjiang, Xu Yifei, Liu Jingxia, Rahman Maryam, Thai Nathan, Leidig William A, Johanns Tanner, Ansstas George, Zhou Alice Y, Pugazenthi Sangami, Dunn Gavin P, Huang Jiayi, Chheda Milan G, Kim Albert H, Leuthardt Eric C, Tran David D. Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial.. Nature communications. 2026. DOI: 10.1038/s41467-026-69522-w.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.